Status:
COMPLETED
A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Human Immunodeficiency Virus
Eligibility:
All Genders
16+ years
Phase:
PHASE3
Brief Summary
A study to test the safety and effect of twice daily raltegravir in a diverse cohort of patients currently infected with human immunodeficiency virus (HIV), where at least 50% are African American and...
Eligibility Criteria
Inclusion
- Patient is HIV positive
- Patient agrees to use (or have their partner use) birth control as defined by the study doctor
Exclusion
- If female, pregnant or breastfeeding
- Patient has used an investigational agent in the last 30 days
- Patient has acute hepatitis
- Patient has received MK0518 (raltegravir) before
- Patient has used another experimental HIV-integrase inhibitor
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
209 Patients enrolled
Trial Details
Trial ID
NCT00764946
Start Date
October 1 2008
End Date
February 1 2011
Last Update
March 21 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.